leisure time -WSS

leisure time

author：focus 2025-10-03 00:40:46 - browse：393

Photography of the US department of health and human services in Silver Spring MD — Manuel Balce Ceneta/AP

An increasing number of medical device companies are submitting fabricated and unreliable data, the Food and Drug Administration noted Tuesday morning. The data comes from third-party labs hired by device firms to test the quality of their products.

Triple-check your data or we’ll reject your device, the FDA warned.

The goal of third-party testing is to ensure a device meets the FDA’s standards in a range of areas, including biocompatibility, sterility, and mechanical performance. The agency wrote that it has noticed an uptick in false data submissions in recent years, particularly from facilities based in China and India. In some cases, the facilities will send data copied from previous device submissions.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： 3 questions for the future of Biden's cancer moonshot

WSS

Infant mortality in U.S. rose last year for first time in decades: CDC

FDA rejects Alnylam's heart disease treatment over insufficient data

Bristol 'take

Live blog: Hearing on CRISPR

How neuroscience research could help beat back brain cancer

Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

entertainment

leisure time

focus

What does generative AI mean for health care? We asked experts

Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

The high cost of giving birth even with insurance

Readout LOUD podcast: The Sarepta saga, decoding biotech hype

The high cost of giving birth even with insurance

Was Amgen transparent enough on FDA's concern on cancer drug?

Guidelines to prevent youth baseball injuries need more muscle

All of Us, NIH's precision medicine initiative, gets a big boost

United colonoscopy coverage change 'may cost lives,' doctors say

What to expect at HLTH 2023, the health care industry conference

focus

All of Us, NIH's precision medicine initiative, gets a big boost

After Sarepta trial failure, Duchenne families brace for more debate

Bill would stop addiction treatment from triggering child abuse inquiry

Medicare proceeds with plan to claw back hospital funds

Prime Medicine says its gene editing passes test in monkeys

AI can decode, harness the power of the humane immune system

explore

hotspot

hotspot

explore